Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer PatientsKeri A. Streby, Timothy P. Cripe|Clinical Cancer Research|2017Cited by 137
Effective <i>in vivo</i> targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumorsGunnar Johansson, Nancy Ratner, Margaret H. Collins et al.|Molecular Cancer Therapeutics|2008Cited by 128
Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulationMark A. Currier, Timothy P. Cripe|Oncotarget|2017Cited by 30
High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to ChemotherapyLeslee Sprague, Timothy P. Cripe|Viruses|2018Cited by 13